Share this article on:

Improved Viral Suppression After Treatment Optimization in HIV-Infected Patients With Persistent Low-Level Viremia

McConnell, Michael J. MD, PhD*; Mier-Mota, Julian BS*; Flor-Parra, Fernando BS*; Martinez-Fernandez, Francisco J.*; Lopez-Cortes, Luis F. MD, PhD*; Viciana, Pompeyo MD, PhD*; Fernandez-Cuenca, Felipe PhD; Perez-Romero, Pilar PhD*

JAIDS Journal of Acquired Immune Deficiency Syndromes: December 15th, 2011 - Volume 58 - Issue 5 - p 446–449
doi: 10.1097/QAI.0b013e3182364513
Brief Report: Basic and Translational Science

Optimizing treatment for patients with persistent low-level viremia is complicated because most genotyping tests are validated for viral loads >1000 copies per milliliter. In this study, genotypes of 92 treatment-experienced patients with persistent low-level viremia were determined using an in-house assay. Based on the resistance profiles obtained from genotyping and patient pharmacologic history, patients were either maintained on their antiviral regimen (n = 51) or received an optimized regimen (n = 41). In the group receiving optimized treatment, undetectable viral loads were achieved in 73.2% at 6 months and at 90.2% at 1 year, indicating that treatment guided by genotyping of patients with low-level viremia is effective in achieving viral suppression.

Supplemental Digital Content is Available in the Text.

*Unit of Infectious Diseases, Microbiology and Preventive Medicine, Instituto de Biomedicina de Sevilla (IBIS)/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain

Microbiology Service, Hospital Universitario Virgen Macarena de Sevilla, Spain.

Supported by the Consejería de Economía, Innovación y Ciencia P06-CTS-01915, Junta de Andalucía; and the Red de Investigación en SIDA (ISCIII RD06/0006), Ministerio de Ciencia e Innovación. M.J.M is supported by the Programme Juan de la Cierva of the Ministerio de Ciencia e Innovación of Spain. P.P.R. was funded by Instituto de Salud Carlos III, Programa Miguel Servet CP05/00226.

The authors J.M.M., L.F.L.C., P.V. and P.P.R. are listed as inventors on a patent registered by the Andalusian Foundation for Health Research of Seville with the Spanish Office of Patents and Trademarks covering the method described in this study. M.J.M. and J.M.M. contributed equally to this work.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (

Correspondence to: Pilar Pérez-Romero, PhD, Unit of Infectious Diseases, Microbiology and Preventive Medicine. Instituto de Biomedicina de Sevilla (IBiS). University Hospital Virgen del Rocío/CSIC/University of Sevilla. Avda Manuel Siurot s/n, 41013 Sevilla, Spain (e-mail: or

Received April 7, 2011

Accepted September 6, 2011

© 2011 Lippincott Williams & Wilkins, Inc.